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INTRODUCTION
Prostate cancer is the second leading cause of cancer death in American
men. The disease prognosis is significantly limited by the finite therapeutic
treatments. The limited treatment options are made worse by the significant
reduction in the quality of life that often results from the severe side effects
produced by these treatments.1 Therefore, any improvements of current
treatments would be advantageous to the clinical setting. Recently, TREK-1, a
tandem-pore domain (K 2P ) potassium channel, has been shown to be
upregulated in prostate cancer, but absent in normal prostate tissue.2 The
observation that TREK-1 expression is correlated with tumor malignancy
suggests that TREK-1 may be a possible target for the development of novel
drugs that target prostate cancer. Interestingly, other subtypes of the K 2P family
also have upregulated expression in several other types of malignancies.2,

3, 4

These observations have prompted many research laboratories to characterize
the role of TREK-1 in cancer cells. However, in order to explore the role of
TREK-1 in cancer cells, pharmacological tools selective for TREK-1 need to be
developed. Specifically, a large-scale screen is needed to identify molecules that
selectively modulate TREK-1.
The K2P Family of Ion Channels
Potassium ion channels are large multi-subunit proteins that include:
voltage-gated potassium channels (K V ), inwardly rectifying potassium channels
(K ir ), and the tandem-pore domain potassium channels (K 2P ).5
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The K 2P family was first identified in 1996, and since then, researchers
have been working to characterize the distinction between the subtypes.6 K 2P
proteins possess two tandem P (pore-forming) domains. The P domain is a
highly-conserved twenty amino acid motif that discriminates for potassium ions.5
P domains are assembled in sets of four to create a functional potassium
channel, and their arrangement is what distinguishes the different potassium
channel families. Whereas the K 2P family members contain two P domains per
subunit and form functional channels as dimers, other potassium channel
families have only one P domain and function as tetramers.5 Structural
differences between the K 2P family and other potassium channels could
potentially be exploited to develop molecules that selectively target members of
the family, such as TREK-1.
Within the known fifteen subtypes of K 2P , TREK-1 is known as a
polyunsaturated fatty acid (PUFA) and stretch-activated potassium channel.7
TREK-1 has low basal activity compared with other members of K 2P family.5
However, this receptor can be strongly activated upon application of arachidonic
acid; this activation is reversible and concentration-dependent. The effect is
specific to unsaturated fatty acids, including oleate, linoleate, arachidonate,
eicosapentaenoate, and docosahexanenoate.5 In contrast to the long, lipophillic
activators, the small molecule, riluzole, is also capable of channel activation.8
Other pharmacological agonists include inhaled anesthetics such as halothane
and isoflurane.4 Activation of the channel can also be caused by environmental
changes including internal acidification, shear stress, cell swelling, and negative
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pressure and physical stretch to the cell membrane.3 Few inhibitors of the
channel have been identified. Galladium and quinidine specifically inhibit TREK1 activity.3
In addition to TREK-1, Other K 2P channels have been shown to be
overexpressed in several malignancies. TASK-3, a close relative of TREK-1, is
amplified in 10% of breast cancers and is overexpressed at a higher frequency in
colon and metastatic prostate cancer.9,

10

One study suggests that TASK-3

overexpression in breast tissue may contribute to tumorgenesis by promoting
cancer cell survival in poorly oxygenated areas of solid tumors.11 Similarly,
TREK-1 has the ability to become activated during an ischemic episode to
protect neuronal function.12 It is hypothesized that during brain ischemia,
endogenous arachidonic acid is released, intracellular pH becomes more acidic,
and neurons swell. These pathological alterations all contribute to activation of
TREK-1, resulting in hyperpolarization, decreased excitotoxicity, and reduced
neuronal damage.12 It is possible that the gene that codes for TREK-1, KCNK2,
may be a tumor survival gene and that TREK-1 upregulation is an adaptation for
the cell or solid prostate cancer tumor to cope with a hypoxic environment.2
Drugs that Target Ion Channels
Several classes of ion channel agonists and antagonists have been
developed, and these modulating drugs are used in therapeutic treatments of
disease states such as epilepsy, hypertension, diabetes, and chronic pain.13 Of
particular relevance to this study is the development of ion channel modulating
compounds that have potential as cancer treatments.14 For example, the
3

compound, SKF96365, an inhibitor of a calcium release–activated Ca+2 (CRAC)
channel, has been shown to inhibit breast tumor metastasis in mouse models.15
Uncovering new treatments that target ion channels clearly have the potential to
improve chemotherapy directly or by enhancing the efficacy of existing agents.
Identifying Selective Modulators of TREK-1
The discovery of specific activators/inhibitors of this receptor needs a
highly efficient identification strategy because the current gold standard for
modulator characterization, electrophysiology, is exceedingly costly and time
inefficient. A method commonly employed to make drug discovery more efficient
is known as High-Throughput Screening (HTS). The goal of HTS is to be able to
take widely diverse chemical agents and analyze them in a designed assay both
accurately and rapidly. The field of HTS greatly relies on automation to make the
process more efficient, accurate, and manageable. Although there are several
advantages and recent improvements made to HTS, the main limitation that still
exists is data analysis and ‘hit’ determination.16 A ‘hit’ is best characterized as a
lead candidate that gives a desired result from a screen. Further analyses of lead
candidates are required to rule out the potential for false positives and negatives.
Current assays for TREK-1 activity are incompatible with HTS.17 Thus it is
the goal of this work to develop methods for screening TREK-1 channel activity
modulators (agonist/antagonist).
HYPOTHESIS
It is hypothesized that TREK-1 potentiates tumor growth in prostate
cancer. Developing a screen to identify molecules that modulate TREK-1 function
4

will provide tools for determining the role of TREK-1 in prostate caner and
potentially lead to the development of novel prostate cancer therapy.
OBJECTIVE
The overall goal of this project is to develop a high throughput screening
assay to identify molecules that either inhibit or activate TREK-1. Validation of
TREK-1 expression and function in the selected cultured prostate cell culture
model system is necessary prior to developing an HTS platform.
MATERIALS & METHODS
The expression of TREK-1 was quantified by Western blot analysis in the
prostate cancer (PC3) cell line. The activity of TREK-1 was measured by the flux
of potassium ions across the cell membrane using a fluorescence-based
detection assay known as Fluorescence Imaging Plate Reader (FLIPR). Using
both of these assays jointly allow for inferences concerning the activity of TREK1 to be made.
Cell Culture
The PC3 human prostate cancer cell line was obtained from American
Type Culture Collection (Rockville, MD). Cells were cultured in Ham’s F-12K
medium (Sigma, St Louis, MO) with 10% fetal bovine serum (FBS) (Glibco). Cells
were routinely passaged every week with 1x TripLE Select (Glibco). All cell lines
were maintained at 37°C in a humidified atmosphere of 5% CO 2 .
Western Blot
Growth media was removed from cultured cells and then the cells
trypsinized with TripLE Select. Growth media was added to the cell solution to
5

neutralize the trypsinization process when detachment of cells was complete.
This cell solution was centrifuged to create a pellet and then the solution was
removed. This pellet was washed with PBS in triplicate and stored at -80°C for
later use. When used, pellets were dissolved with ice-cold homogenization buffer
(Roche lysate product # 04719964001) with 1:100 dilution of Halt Protease
Inhibitor Cocktail (Pierce). Sonification for 20 seconds in triplicate of the lysate
was used for cell disruption. The membrane fraction was purified by
centrifugation at 20,000 xg for 30 h at 4°C.
A protein assay protocol (Bio-Rad) was used to quantify protein content in
lysate.18 This was a dye-binding assay in which a differential color change of a
dye (Coomassie Brilliant Blue G-250) occurs in response to various
concentrations of protein. The absorbance maximum for an acidic solution of
Coomassie Brilliant Blue G-250 dye shifts from 465 nm to 595 nm when binding
to protein occurs.18 A spectrophotometer was used to collect absorbance. Beer’s
law was applied for accurate quantification of protein concentration after
development of a standard curve.
Proteins were separated by SDS-PAGE on a 10-14% gel (Lonza).
Prestained protein standards (Bio-Rad) were used as a protein ladder. Samples
were blotted onto nitrocellulose (Bio-Rad), and the membrane blocked with 1%
bovine serum albumin in TBS/0.1% Tween 20. TREK-1 was detected with a
polyclonal rabbit antibody raised against a portion of the NH2-terminal tail of the
channel (Alomone Laboratories), followed by goat anti-rabbit IgG conjugated with
horseradish peroxidase (Santa Cruz). The immunoreactive bands were
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visualized by incubation with enhanced chemiluminescence reagent (Qiagen).
Equal loading of samples was monitored by measuring the abundance of actin
on the same membrane.
Blots were stripped using Abcam’s medium stripping solution [1.5 g
glycine, 100 mg SDS, 1ml Tween 20, pH 2.2, quantity to 100ml ultrapure
water].19 Membranes were incubated for two 10-minute washes of medium
stripping solution, then two 10-minute washes of PBS, followed by one 5-minute
wash of Tris buffer solution and 0.1% Tween 20 (TTBS), and one 5-minute
TTBS. After the wash, the blot was prepared for re-blocking with primary and
secondary antibodies.

Western Blot Analysis
Visualization of immunoreactive bands was performed using
chemiluminescence and captured an AlphaInnotech digital imager. Quantification
of the bands was completed with PDQuest software which determines the value
of intensity of each band marked by TREK-1 antibody.
Fluorescence Imaging Plate Reader (FLIPR)
A membrane polarization assay from Molecular Devices was assessed for
use as an indicator of TREK-1 activation in the PC3 prostate cancer cell line.
This assay uses fluorescence detection in a fluorescence imaging plate reader
(FLIPR, Molecular Devices). In this assay, changes in cell membrane potential
control the partitioning of a fluorescent indicator dye into and out of the cell, with
use of a cell impermeable fluorescence quencher. The properties of the two
separate compounds in an in vitro experiment allow the indicator dye to escape
7

the inhibitor, thus more dye in the cell results in an increase in measured
fluorescence.
Media used was phenol red-free DMEM/F12 (Sigma #D2906) that was
made with 10% FBS (Gibco) to plate PC3 cell lines. Cells were plated 6.4 x 104
cells/well in 100ul of media 14-hours before the experiment in 96-well flat-bottom
black plates with clear bottoms (Costar #3603) and incubated in 5% CO 2 at 37°C
overnight. FLIPR Membrane Potential Assay (R8042) was purchased from
Molecular Devices which contains Blue Dye and Hank’s BSS + 20mM Hepes.
Before placing on plate reader, Blue Dye was reconstituted with 10 ml of Hank’s
BSS buffered with 20 mM Hepes and 100ul of solution was placed on top of
media in each well. This was incubated at room temperature (22°C) for 1 hour.
All compounds tested were stored as stock solutions in ethanol and were diluted
in

10X PBS [1.37M NaCl, 101.6mM Na 2 HPO 4 , 17.6mM KH 2 PO 4, pH 7.4]

containing either 30 mM or 100 mM KCl prior to conducting experiments.
FLIPR Analysis
FlexStation II (Molecular Devices) was used to read the fluorescence
output. Methodology for instrument setup included setting SoftMax Pro 4.8
Software to do a “Flex” kinetic assay. Fluorescence detection parameters
included: excitation wavelength 530 nm, Emission wavelength 565 nm, and
Emission cut-off 550 nm. A MatLab analysis program was used to plot the
average of sample replicates versus time. The program then determines the
lowest point (minFL) between points 3-54 seconds (provided drug is added at
point =20 seconds) and picks the highest point (maxFL) between points 3-54
8

seconds of the plotted averages. The difference between maxFL and minFL
becomes the new mean difference in fluorescence. The standard deviation was
also calculated. The program then performs a t-test on the all of the mean
differences in fluorescence of each sample. This was compared to the controls to
determine significance.
RESULTS & DISCUSSION
Protein Analysis of TREK-1
The Western blot method was chosen for its ability to quantify TREK-1
protein expression. This method has the ability to measure proteins that are
actively being maintained in the cell membrane. The use of a Western blot is a
gold standard for protein quantification and an appropriate tool for TREK-1
detection. The Figure 1 shows an immune blot for TREK-1 and actin in the PC3
cell line.
The only antibody manufactured to target TREK-1 protein for Western blot
analysis has non-specific binding to several other proteins in PC3 cells, as
apparent in Figure 1A. In response to the non-specific binding of the antibody,
the manufacturer created a negative control antigen to provide evidence that the
antibody was targeting TREK-1. This antigen was incubated with the primary
antibody before application to the membrane. The antigen is designed to prevent
binding of TREK-1 antibody to TREK-1 protein. If the imaged band corresponding
to TREK-1 was absent in the incubation with antigen (compared to antibody
incubation alone) it can be inferred that TREK-1 is present and interacting with
the antibody, confirming TREK-1 expression in PC3 cells. However, as shown in
9

Figure 1C, the absence of a band after incubating with the primary antibody with
the antigen was not observed.
Another concern when performing a Western blot to probe for TREK-1
protein was determining an appropriate loading control for comparison.

A

loading control is a ubiquitous protein that is measured on the same blot as the
studied proteins to verify that equivalent amounts of protein are loaded in each
lane.19 Based on the molecular weight of available loading controls, two different
loading controls could have been used for TREK-1 quantification: actin (43 kDa)
and GAPDH (37 kDa). Due to TREK-1 protein’s size (45 kDa), it was important to
allow sufficient band separation during SDS-PAGE for distinguishing TREK-1
from the loading controls. Although GAPDH would be better resolved from
TREK-1 by molecular weight, it has been shown to vary widely in expression
levels across different cell lines and was therefore not ideal for comparison.21
Therefore, actin was used as a loading control for the purpose of quantification.
The blot shown in Figure ID was re-probed for actin and imaged, after stripping
TREK-1 primary antibody. This figure shows that there is less actin protein
compared to TREK-1 in Figure 1A, although it is possible that some protein was
lost during the stripping process.
Because actin and TREK-1 proteins are too similar in size and TREK-1
has non-specific binding, the two proteins cannot be differentiated conclusively
from one another. It cannot be determined when looking at Figure 1A, if the
TREK-1 antibody is non-specifically binding to similar sized proteins such as
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actin or appear to be expressed at a higher concentration than what exists within
the cell membrane.
The factor limiting the detection of TREK-1 is the antibodies’ lack of
specificity for the TREK-1 receptor. The antibody used for the purpose of TREK1 quantification in this study failed to be sufficiently selective. Therefore, it is
necessary to use additional methods to better confirm TREK-1 expression in PC3
cell line.
TREK-1 Activation
The FLIPR assay was selected to measure TREK-1 activity based on its
ease of use, the ability to conduct several experiments in a short time frame, and
HTS compatibility. Other accepted methods to measure channel activation are
extremely limited due to time and training requirements. The most common
alternative method to measure membrane potential involves electrophysiology
and often requires several months (or years) to master its use. Patch-clamp
electrophysiology in mammalian cells is still the gold-standard assay for
measurements of ion channels.22 However, electrophysiological measurements
are not compatible with HTS, since only a few compounds can be screened on
an individual cell at any given time.
The FLIPR assay is unique in its mechanism of action. The indicator dye
used in this assay is a derivative of the potential-sensitive dye, bis-(1,3dibutylbarbituric acid) trimethine oxonol (Dibac 4 (3) dye, or bis-oxonol).23 Until
FLIPR, Dibac dyes had been limited by the excessive time necessary for
incubation which ultimately leads to cell toxicity.23 Molecular Devices, Inc.
11

created two separate formulations for the Membrane-Potential Assay that require
less incubation time which helps maintain the viability of the cells and helps
produce higher quality of data. The systems combine the indicator dye with a dye
quencher that inhibits the indicator dye from fluorescing when not inside the cell.
The mixture of dyes helps to increase the possibility of a successful assay with a
specific cell line/ion channel.24
The fluorescent indicator dye in the kit is a lipophilic, anionic dye that can
partition across the cytoplasmic membrane of live cells dependent upon the
potential across the plasma membrane. The quenching dye does not enter the
cell but masks all extracellular fluorescence of the indicator dye.23 Therefore,
during application of these compounds to the cells, baseline fluorescence was
measured and no significant change in fluorescence occurred unless the
electrical potential equilibrium is disrupted. This could occur by either mechanical
and/or pharmacological means.
When cells are depolarized, more dye enters the cells, causing an
increase in fluorescence signal.23 The dye crosses the cell membrane passively
because the fluorescent dye is anionic and is not believed to be carried via a
transporter. Conversely, when the cells are hyperpolarized, dye exits the
cells, resulting in a decrease in fluorescence signal.23
Due to the nature of TREK-1, if potassium is at higher concentration
outside the cell and the protein is activated, the channel will attempt to equilibrate
the potassium concentrations by pulling potassium into the cell. The influx of
potassium will increase the membrane potential resulting in an increase of dye in
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the cell, with a concomitant increase in fluorescence measured. Since potassium
flux could be affected by the activity of other potassium channels, the assay was
optimized to establish specific activation of TREK-1 using known agonists and
antagonists. The assay was calibrated through the use of carefully controlled,
high concentration doses of potassium to induce potassium influx in addition to
either TREK-1 activators (expected to further increase potassium influx) or
inhibitors (expected to result in diminished potassium influx).
It is important that the activators and the inhibitors used in this assay were
relatively selective for TREK-1 so that TREK-1 activation could be discriminated.
Known

TREK-1-specific

activators,

docosahexaenoic

acid

(DHA)

and

eicosapentaenoic acid (EPA), were used to limit interactions with other
potassium receptors.3 EPA and DHA are both long chain fatty acids and can
potentially increase membrane permeability to potassium. In addition to PUFAs,
riluzole, another known activator of TREK-1, is a much smaller compound
without the capability of inserting itself into the membrane. For this reason,
riluzole was used as a TREK-1 activator in the fluorescence assay. Quinidine, a
known non-specific inhibitor of TREK-1, was used as the antagonist when
conducting dose-response curves.3
TREK-1 Activation – Preliminary Results
The FLIPR assay was optimized for assessing TREK-1 channel activity.
Preliminary testing using known agonists DHA and EPA was necessary to
determine whether the FLIPR platform could be used to measure the membrane
potential activity for the prostate cancer PC3 cell line (Figure 2).
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Preliminary findings, as shown in Figure 2, help validate the hypothesis.
Within seconds of addition of an agonist and potassium ions, an instantaneous
depolarization occurred. In the presence of a TREK-1 activator, the increase in
fluorescence was significant when compared to the control. An increase in
fluorescence was also observed in the agonist-free controls; however, this
fluorescence signal change was not significant when compared to lower drug
concentrations (Table 1). There are many factors contributing to why an increase
in signal baseline was observed for the controls in the absence of an agonist.
Stress on the cells from additional pressure changes during pipette application of
control solution could have potentially resulted in activation of TREK-1 since
pressure and shear stress opens the channel. Another explanation for this
observation could be from a cellular response to an increase in ethanol
concentration. Reported observations demonstrate cellular activity changes in
ethanol concentrations less than 0.05%.25 It is also possible that there was a
cellular response to equilibrate potassium concentrations. Due to the presence of
these potential factors, controls were performed in triplicate.
A confounding issue observed upon analysis of the preliminary results
came from a decreased fluorescence signal at higher drug concentrations. At 20
µM concentrations of both DHA and EPA, the signal was determined to be
equivalent to that of the control. However, it has been reported that
concentrations of up to 100 µM of DHA lead to activation of TREK-1.26 Although
not previously reported, it was hypothesized that the drug might act upon offtarget sites, thus mimicking an "antagonist" effect at high concentrations. This
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was an interesting observation, and it was a consistent trend which appeared to
be reproduced in other unrelated cell lines tested including MCF-7 and MDA-MB231 breast cancer cell lines. Therefore, it was determined to be due to another
factor. It is possible that the receptors were saturated with compounds at these
higher concentrations but with inadequate extracellular potassium to elicit a
response required to produce the level of depolarization necessary for an influx
of the dye. If this was true, there are two adjustments that should be made to the
assay: either increase the potassium content or decrease the drug concentration.
When accounting for the amount of potassium in the current drug design,
there was not a significant difference in ion concentration at baseline compared
to post-drug addition. Potassium accounted for approximately 5.6 mM potassium
from the cell media (calculated from the buffer composition) and the FLIPR dye.
After the drug addition, there was only an overall 7.8 mM potassium difference.
Most electrophysiological studies with the FLIPR assay recommend a difference
of 15 mM potassium.23 Therefore, an adjustment of the potassium content was
necessary to produce greater signal. An increase of potassium was made to
ensure that after application of the drug, there would be a 15 mM potassium
concentration difference. A reduction in drug concentrations also led to a
decrease in observed fluorescence. Therefore, this procedural optimization
eliminated the anomaly observed at high drug concentrations.
TREK-1 Activation – DHA, EPA, & Riluzole
After accounting for the potassium concentration, results improved for
EPA (Figure 4), but still persisted when DHA was used (Figure 3). It is possible
15

that there is still not enough of a potassium gradient post-drug application of
DHA. However, because the structure of DHA is closer to arachidonic acid (AA)
than EPA and AA is known for its potent activation of TREK-1 (Figure 7), 27 it is
likely that DHA is a more potent activator of TREK-1 than EPA. This indicates
that DHA requires more available potassium at test concentrations to see
anticipated effects. It is also possible that DHA is more capable inserting itself
into the cell membrane than EPA due to having a longer carbon chain, which
would increase its lipophilicity. If DHA were inserting itself rather than acting on
the receptor, this could disrupt the cell membrane and result in either TREK-1
activation or potentially another compensating mechanism that resists membrane
depolarization.
For comparison with the PUFAs, the small molecule riluzole (Figure 7)
was tested to compare fluorescence responses. Riluzole demonstrated a
consistent dose-dependence and exhibited significant responses at all
concentrations tested when compared to control (Figure 5). It is hypothesized
that the effects observed are not necessarily due to cell activity but due to a
chemical interaction with the dye and/or media upon treatment.
TREK-1 Activation – Negative Control
When using fluorescence drug assays, it is important to verify that the
drugs do not interact with the fluorescent dyes in the absence of cells. If an
interaction occurs, this can indicate either a false-positive or negative response.
Molecules fluoresce based upon energy state relaxation and is dependent upon
conformation of the structure. DHA could be interacting with the FLIPR dye
16

resulting in decreased fluorescence when there are higher drug concentrations
present. Figure 6 shows that there is potentially an interaction occurring between
DHA and the dye. It is also possible that the observed decrease in fluorescence
after drug addition is a dilution effect on the dye rather than a quenching of the
fluorescent molecule. However, the change in fluorescence is very significant
and lends itself to being attributed to a physical interaction.
In-depth chemical analysis to determine the DHA’s interaction (Figure 6)
with the dye is difficult to perform. Because the fluorescent dyes are premixed,
there is no way to determine if the dye interaction with DHA is due to the
associated complex of the quencher and indicator or by a single component. It is
possible that a decrease in fluorescence is due to promotion of the ionic
association between the indicator and quencher, or that DHA aids in the
quenching of the indicator. However, it is plausible that a combination of the two
mechanisms exists.
TREK-1 Activation – Antagonist Assay: Riluzole & Quinidine
Riluzole produced the most reliable data for this platform (Figure 5). The
smaller compound, when tested, lacked the support for other underlying
mechanisms that explain observations noted with the PUFAs. This molecule
produced cleaner data; therefore, future studies of the FLIPR can be performed
using riluzole to produce an appropriate HTS for TREK-1.
To sufficiently determine that riluzole is acting on TREK-1, an inhibitor of
the receptor is necessary to block the actions of the drug so that its activity can
be verified as ligand-mediated. As stated earlier, there are no specific
17

antagonists for TREK-1, but quinidine at high concentrations (IC 50 = 100µM)
results in TREK-1 activation.1 Table 4 lists riluzole’s change in fluorescence,
observed in PC3 cells at specific concentrations as well as in the varying
concentrations of quinidine. Unfortunately, no reversible inhibition was observed
for riluzole in the presence of quinidine.
Dose-response curves are extremely difficult to conduct when known
agonists and antagonists lack specificity for the target. This makes interpretation
challenging to determine which parameters to adjust to produce more reliable
data. From this data, riluzole concentration should be increased in the assay.
Further analysis should be performed to assess the validity of the results
gathered.
CONCLUSION AND FUTURE DIRECTIONS
The utility of an HTS assay is limited by the selectivity of the assay. In the
case of TREK-1, there are no known selective inhibitors of the channel, and
therefore, an HTS assay for TREK-1 cannot be produced with the assurance of
differentiating the individual channel from other related potassium receptors.
However, using the FLIPR assay to create a platform that is selective for
potassium channels can still assist in the discovery of activators and inhibitors of
TREK-1. Screening compounds through this method can then produce a more
finite list of molecules to be tested in electrophysiology studies to confirm or deny
TREK-1 activation. Future discoveries from this methodology can then be
integrated into the FLIPR assay to improve its selectivity for the channel.
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For the purposes of developing an HTS, there are several challenges
associated with conducting the FLIPR assay. First, to ensure that only potassium
channel activation is occurring, the assay must be designed to limit other channel
involvement. One potential way to solve this would be to remove or limit
uninvolved ions such as magnesium and calcium in assay solutions. The
solutions applied during these experiments contained the activating and inhibitory
compounds in diluted potassium ion solutions. However, not all ions can be
completely removed from the solutions. This is because a balance of ions needs
to exist inside and outside the cell to maintain a proper electrochemical gradient.
Without the minimum required ions, a cell will not be permitted to perform the
necessary biological activities, and TREK-1 activity will not be accurately
depicted.
The second challenge with the FLIPR assay was how to measure
specifically for TREK-1 ion channel activity, because this assay measures the
activity of all potassium channels. One method to discriminate between particular
ion channel activities is through the use of pharmacological agents. The
expectation was that by measuring a dose response with highly-selective TREK1 agonists and antagonists, the fractional potassium flux activity due to TREK-1
could be measured. However, it is still possible that the selective agents could be
facilitating undiscovered reactions with other ion channels and thus, interfering
with measurements.
However to facilitate solutions to these problems, future plans could
involve using genetically modified cell lines to create cells with and without
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TREK-1 receptors. A comparison of response between the two cell lines could
help differentiate TREK-1 specific activities and modulators when screening
libraries. There are two commonly practiced methods to genetically modify the
cell lines: insertion of a gene for human TREK-1 to up-regulate its protein
expression or the use of short interfering RNA (siRNA), a gene silencer, directed
at knocking down TREK-1 expression. Depending on the cell line enlisted for the
foundation of the screen, one method may be more optimal to use than the other.
For example, in the case of PC3 cells, TREK-1 expression has been
documented,

2

so the use of commercially available siRNA may be more

appropriate. However, this method may be only partially effective at eliminating
gene expression and is highly dependent on the cell line used.28 Depending upon
the amount of overexpressed TREK-1 in PC3 cells and the efficiency of siRNA in
this particular cell line, gene silencing could produce a poor model to be used for
comparison. This is why it is beneficial to produce better tools to quantify TREK-1
in specific cells lines so that data can be quantitative in nature. That
notwithstanding, until these new tools are produced, siRNA presents a future
opportunity and a new direction for this project.
With regard to the work presented here, future tool developments could
easily improve the methodology of this study. For instance, it would be beneficial
to improve TREK-1 immunodetection for Western blot analysis. One way to
accomplish this would involve producing a protein-tag-fused recombinant TREK1 to serve as a more specific epitope, and then using an antibody against that
epitope for detection rather than TREK-1 for enhanced specificity. If the
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constructed epitope was sufficiently orthogonal, it would result in highly specific
visualization of only epitope-fused TREK-1 protein.29 Another alternative for
quantification of TREK-1 is reverse transcriptase-polymerase chain reaction (RTPCR), which measures mRNA levels rather than expressed protein.
The Western blot method was specifically chosen for the detection and
quantification of TREK-1 expression in these cells due to its ability to measure
the current protein that is actively being maintained in the cell membrane.
Alternatively, for the purpose of quantifying TREK-1 expression in PC3 cells,
another assay is available that measures gene transcript levels, encoding TREK1 protein. This method, RT-PCR, can show that TREK-1 protein has the
capability of being expressed, but does not confirm protein expression.
Therefore, it may not be reliable for validating TREK-1 expression because
determining the presence of coding material does not verify that the code is
translated into an active protein channel on the cell surface. Therefore, the use of
a Western blot is usually the ideal method for protein visualization, but in regards
to TREK-1, until another antibody is developed, RT-PCR may provide more
conclusive evidence.
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APPENDIX
Figures & Tables

22

23

Table 1 – Agonist Assay: DHA and EPA t-Test Analysis
Drug Concentration Mean‡ Difference in FL
(RFU)§
DHA
20 µM
227395
10 µM
360476
5 µM
465987
EPA
20 µM
230357
10 µM
388085
5 µM
538153

Mean‡ Difference in FL
of control (RFU)§
231427
231427
231427
231427
231427
231427

P –value
0.86
**
**
0.92
**
**

< 0.01 (**) < 0.05 (*)
‡ Denotes mean of eight replicates
§ Represents the lowest point (minFL) between points 3-54 seconds (provided drug is added at point
=20seconds) and selects the highest point (maxFL) between points 3-54 seconds of the plotted
averages. The difference between maxFL and minFL becomes the new mean difference in
fluorescence
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Table 2 – Agonist Assay: DHA t-Test Analysis
Drug Concentration
DHA

2.50 µM
1.25 µM
625 nM
312 nM
156 nM
78 nM

Mean‡ Difference
in FL (RFU)§
193335
210946
205901
209364
205772
213207

Mean‡ Difference in
FL of control (RFU)§
101771
101771
101771
101771
101771
101771

P –value
**
**
**
**
**
**

< 0.01 (**) < 0.05 (*)
‡ Denotes mean of eight replicates
§ Represents the lowest point (minFL) between points 3-54 seconds (provided
drug is added at point =20seconds) and selects the highest point (maxFL)
between points 3-54 seconds of the plotted averages. The difference between
maxFL and minFL becomes the new mean difference in fluorescence
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Table 3 – Agonist Assay: EPA t-Test Analysis
Drug Concentration
EPA

10.00 µM
2.50 µM
1.25 µM
625 nM
312 nM
156 nM
78 nM

Mean‡ Difference
in FL (RFU)§
236894
220832
232165
212318
227373
213578
237785

Mean‡ Difference in FL
of control (RFU)§
123392
123392
123392
123392
123392
123392
123392

P –value
**
**
**
**
**
**
**

< 0.01 (**) < 0.05 (*)
‡ Denotes mean of eight replicates
§ Represents the lowest point (minFL) between points 3-54 seconds (provided drug is added
at point =20seconds) and selects the highest point (maxFL) between points 3-54 seconds
of the plotted averages. The difference between maxFL and minFL becomes the new mean
difference in fluorescence
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Table 4 – Antagonist Assay: Riluzole +/- Quinidine t-Test Analysis
Drug

Concentration

Riluzole

20 µM
10 µM
5 µM
2.5 µM
1.25 µM
626 nM
313 nM
156 nM
78 nM
2.5 µM
2.5 µM
2.5 µM
2.5 µM
2.5 µM
2.5 µM
2.5 µM
2.5 µM
2.5 µM

Presence of
Quinidine
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
800 µM
400 µM
200 µM
100 µM
50 µM
25 µM
12.5 µM
6.5 µM
3.2 µM

Mean‡ Difference
in FL (RFU)§
270682
254453
246234
233408
209144
232773
206306
203628
175393
231177
200883
232180
207157
314819
200766
213871
213945
203339

Mean‡ Difference in
FL of control (RFU)§
113523
113523
113523
113523
113523
113523
113523
113523
113523
211162
211162
211162
211162
211162
211162
211162
211162
211162

P –value
**
**
**
**
**
**
0.07
0.33
*
0.11
0.57
0.27
0.85
**
0.55
0.82
0.82
0.52

< 0.01 (**) < 0.05 (*)
‡ Denotes mean of eight replicates
§ Represents the lowest point (minFL) between points 3-54 seconds (provided drug is added at point =
20 seconds) and selects the highest point (maxFL) between points 3-54 seconds of the plotted averages.
The difference between maxFL and minFL becomes the new mean difference in fluorescence
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Drug/Controls applied at twenty seconds and diluted in 116.4mM K+ and 1% EtOH in absence of cells
10X PBS [1.37M NaCl, 98.8mM KCl, 101.6mM Na 2 HPO 4 , 17.6mM KH 2 PO 4, pH 7.4]
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Figure 7: TREK-1 Modulators

Arachidonic Acid (AA)

Docosahexaenoic Acid (DHA)

Eicosapentaenoic Acid (EPA)

Riluzole (RIZ)

Quinidine
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